Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
FBR Capital Remains Bullish on Advaxis (ADXS) Following Conference Call About FDA IND Clinical Hold
October 7, 2015 7:49 AM EDTFBR Capital reiterated an Outperform rating and $34.00 price target on Advaxis (NASDAQ: ADXS) following a conference call and webcast. The call was to discuss the announcement that its Investigational New Drug (IND) application for axalimogene filolisbac (AF) was placed on clinical hold by the FDA, affecting four clinical trials with AF in cervical cancer.
Analyst Vernon Bernardino commented, "Advaxis, after market... More
